Evidence for a defined syndrome is summarised with the conclusion that this is overwhelming. Causation is explored and a practical way of identifying and managing the syndrome in primary care is detailed; this includes the necessary lifestyle changes, the appropriate use of drug therapy and the selective use of surgery.
Get full access to this article
View all access options for this article.
References
1.
ReavenG.M.Role of insulin resistance in human disease. Diabetes, 1988; 21:296–309.
2.
MeigsJ.B.Epidemiology of the Metabolic Syndrome. Am J Managed Care, 2002; 8(11 Suppl.):283–292.
3.
HaffnerS.M., SternM.P., HazudaH.P., et al.Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of diabetes?. JAMA, 1990; 263:2893–2898.
4.
SternM.P., HaffnerS.M.Body fat distribution and hyperinsulinaemia as risk factors for diabetes and cardiovascular disease. Arteriosclerosis, 1986; 6:123–130.
5.
HaffnerS.M., MykkanenL., FestaA., et al.Insulin resistant prediabetic subjects have more atherogenic risk factors than insulin sensitive prediabetic subjects. Implications for preventing coronary heart disease during the prediabetic state. Circulation, 2000; 101:975–980.
6.
WilsonP.N.F., KanneB.W.B., SilbershalzI.T., et al.Clustering of metabolic risk factors and coronary heart disease. Arch Intern Med, 1999; 159:1104–1109.
7.
SchmidtM.I., WatsonR.L., DuncanB.B., et al.Clustering of dyslipidaemia and hypertension and its association with fasting insulin and central and overall obesity in a general population. Metabolism, 1996; 45:699–706.
8.
MeigsJ.B.Invalid commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol, 2000; 152:908–911.
9.
DesprèsJ.P., LamarcheB., MauriegeP., et al.Hyperinsulinaemia as an independent risk factor for ischaemic heart disease. N Eng J Med, 1996; 334:952–957.
10.
PyoralaM., MiettinenH., LaskoM., et al.Hyperinsulinaemia predicts coronary heart disease in healthy middle-aged men. The 22-year follow up results of the Helsinki Policemen Study. Circulation, 1998; 98:398–404.
11.
MeigsJ.B., D’AgostinoR.B., WilsonP.W.F., et al.Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes, 1997; 46:1594–1600.
12.
WilsonP.N.F., D’AgostinoR.B., PariseH., et al.The metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus [abstract]. Diabetes, 2002; 51(suppl):980.
13.
AlbertiK.G.M., ZimmetP.Definition and Classification of Diabetes Mellitus and its Complications Part 1. Diagnosis and Classification of Diabetes Mellitus. Report of a WHO Consultation. Diabetes Med, 1998; 15:539–553.
14.
National Cholesterol Education Program. Executive Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. (Adult Treatment Panel III) JAMA, 2001; 285:2486–97.
15.
PearsonT.A., MensalG.A., AlexanderR.W., et al.Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 2003; 107:499–511.
16.
XiangA.H., AzonS.P., RaffelR.J., et al.Evidence for joint genetic control of insulin sensitivity and systolic blood pressure in Hispanic families with a hypertension proband. Circulation, 2001; 103:78–83.
17.
LieseA.D., Mayer-DavisE.J., TyrolerH.A., et al.Familial components of the multiple metabolic syndrome. The ARIC study. Diabetologia, 1997; 40:963–970.
18.
CarmelliD., CardonL.R., FabsilzR.Clustering of hypertension, diabetes and obesity in adult male twins: same genes or same environments?. Am J Human Genet, 1994; 55:566–573.
19.
EdwardsK.L., NewmanB., AustinM.A., et al.Heritability of factors of the insulin resistance syndrome in women twins. Genet Epidemiol, 1997; 14:241–253.
20.
HillA.J., RogersP.G.Food intake and eating behaviours. In: KopelmanP.G., StockM.J. editors. Clinical Obesity. Oxford: Blackwell Science; 1998. p. 86–111.
21.
HanT.S., Van LeerE.M., SeidellJ.C., et al.Waist circumference action levels in the identification of cardiovascular risk factors – prevalence study in a random sample. Brit Med J, 1995; 311:1401–1405.
22.
HarkL., DeenD.Jr.. Taking a nutritional history: a practical approach for family physicians. Am Fam Physician, 1999; 59:1521–1528.
23.
PearsonT.A., MensalG.A., AlexanderR.W., et al.Markers of inflammation and cardiovascular disease: application of clinical and public health practice. A statement for health care professionals from the Centres for Disease Control and Prevention and the American Heart Association. Circulation, 2003; 107:499–511.
24.
JungR.T.Obesity as a disease in Ed. Finer N British Medical Bulletin, 1997; 53(2):307–321.
25.
DeenD.Metabolic Syndrome: Time for Action. American Family Physician, 2004.
26.
SarisW.H.M.Physical activity in the treatment of obesity. Obesity – The Threat Ahead, 1998; 24–25.
27.
RossR., DagnoneD., JonesP.J., et al.Reduction in obesity and related co-morbid conditions : a diet-induced weight loss or exercise induced weight loss in men. A randomised control trial. Ann Intern Med, 2000; 36:75–88.
28.
HooperL., BartlettC., DaveyS.G., et al.Advice to reduce dietary salt for prevention of cardiovascular disease. Cochrane Database Syst Rev, 2004; 2): CD003656.
29.
HooperL., SummerbellC.D., HigginsJ.P., et al.Reduced or modified dietary fat for prevention of cardiovascular disease. Cochrane Database Syst Rev, 2004; 2): CD002137.
30.
GrundyS.M., AbateN., ChandaliaM.Diet composition and the metabolic syndrome: What is the optimal fat intake?. Am J Med, 2002; 113(suppl. 9B):255–298.
31.
GarrowJ.S.Treatment of obesity. Lancet, 1992; 30:409–413.
32.
LeanM.E.J., JamesW.P.T.Prescription of diabetic diets in the 1980s. Lancet, 1980; 723–725.
33.
FormigueraX.Diet in obesity management: appraisal and recommendations. In: Obesity: The threat ahead p.22. European Congress on Obesity (1999).
34.
Bolton-SmithC., WoodwardM.The prevalence of overweight and obesity in different fat and sugar consumption Groups [abstract]. Proceedings of the Nutrition Society, 1993; 52:383A.
35.
GinsbergH.N.Treatment for patients with the metabolic syndrome. Am J Cardio, 2003; 91:29E–39E.
36.
GaedeP., VedelP., LarsenH., et al.Multifactional intervention and cardiovascular disease in patients with type 2 diabetes. N Eng J Med, 2003; 348:383–393.
37.
Royal College of Physicians (1998). Clinical Management of overweight and obese patients with particular reference to the use of drugs. R.C.P.London.
38.
WaineC.Obesity and Weight Management in Primary Care. Oxford: Blackwell Science; 2002, p. 65.
39.
ZavoralJ.H.Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertension, 1998; 16:2013–2017.
40.
LingardeF., et al.The effect of orlistat on body weight and coronary heart disease risk profile in obese patients. The Swedish Multimorbidity Study. J Int Med, 2000; 248:245–254.
41.
HauptmanJ.Orlistat in the long-term treatment of obesity in primary care settings. Archives of Family Med, 2000; 9:160–167.
42.
DavidsonM.H.Weight control and risk factor reduction in obese subjects treated for two years with orlistat. JAMA, 1999; 281(3):235–242.
43.
BarbePL, HanotinC, LouvetFP. Efforts of sibutramine on the body composition following weight loss in obese patients. 1999.
FinerN., BloomS.R.Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Diabetes Obesity and Metabolism, 2000; 2(2):105–112.
46.
JamesW.P.T., AstrupA., FinerN., et al.Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet, 2000; 356:2119–2125.
47.
KralJ.G.Surgical treatment of obesity. In: StockM.J., KopelmanP.G. editors. Clinical Obesity. Oxford: Blackwell Science; 1998. p. 545–563.
48.
NashundI., AgtenG.Is obesity surgery worthwhile?. Obesity Surgery, 1999; 9:36.
